# PRRT for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Patient's Guide to Treatment and Sequencing PRRT (peptide receptor radionuclide therapy) is a targeted radiation treatment that has proven highly effective for many patients with advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that express somatostatin receptors. Clinical trials including NETTER-1 and NETTER-2 show that treatment with **177Lu-DOTATATE** significantly delays tumor growth and improves symptoms, with progression-free survival improved from about 8.4 months to 22.8 months in certain grade 2 and grade 3 tumors. However, deciding when to use PRRT — early, late, or as a re-treatment — remains complex, and individual factors like tumor grade, kidney function, and disease burden play major roles. A personalized, multidisciplinary approach is essential for maximizing PRRT's benefits and minimizing risks. # PRRT for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Patient's Guide to Treatment and Sequencing ## Table of Contents - Key Points - Background: What Are Neuroendocrine Tumors? - How PRRT Works - How This Review Was Conducted - Key Findings: Evidence for PRRT - Quality of Life and Symptom Control - Imaging Before and During PRRT - Sequencing PRRT in Advanced GEP-NETs - Unique Challenges and Safety Considerations - Ongoing Clinical Trials - Clinical Implications - Limitations - Recommendations for Patients - Frequently Asked Questions - Source Information ## Key Points - PRRT with 177Lu-DOTATATE is a targeted radiation treatment for advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors that express somatostatin receptors. - In the NETTER-1 trial, median progression-free survival was 8.4 months with octreotide alone and not reached with PRRT; overall survival difference was not statistically significant, likely due to crossover. - In the NETTER-2 trial, first-line PRRT improved median progression-free survival to 22.8 months versus 8.5 months with high-dose octreotide in grade 2 and grade 3 SSTR-positive GEP-NETs. - PRRT can control tumor-related symptoms and improve quality of life, but may cause kidney toxicity, blood count suppression, and rarely a hormonal crisis; kidney function and hydronephrosis must be evaluated first. - Treatment typically involves four cycles about 8 weeks apart, with imaging 1–3 months after completion; apparent early tumor growth may be pseudo-progression from inflammation, not true progression. ## Background: What Are Neuroendocrine Tumors? Neuroendocrine neoplasms (NENs) are a highly diverse group of malignancies that can arise in several different organs throughout the body. Their clinical behavior varies significantly based on the tumor's grade and whether it secretes hormones. The incidence and prevalence of NENs is rising. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) make up about 70% of cases. They are now the second most prevalent gastrointestinal neoplasm after colon cancer. NENs include well-differentiated neuroendocrine tumors (WD-NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-NENs. WD-NETs are further divided into three grades based on the **Ki-67 proliferation index** (a measure of how fast tumor cells are dividing) and/or mitotic count. These grades are grade 1 (G1), grade 2 (G2), and grade 3 (G3). One unique feature of NENs is their expression of **somatostatin receptors (SSTRs)** — proteins on the cell surface that belong to a family of G-protein-coupled 7-transmembrane receptors. Most well-differentiated GEP-NETs express these receptors. By contrast, high-grade NETs and NECs can lose SSTR expression, and that loss is associated with a worse prognosis. The membranous expression of SSTRs has been harnessed for **theranostic** (therapy plus diagnostic) applications. SSTR-targeting radioligands are used both for functional imaging and for treatment. NENs are also commonly imaged with radiolabeled DOTA-conjugated peptides such as 68Ga-DOTATATE, 68Ga-DOTATOC, or 64Cu-DOTATATE using positron emission tomography/computed tomography (PET/CT) or PET/magnetic resonance imaging (MRI). Nearly 50% of NET patients have metastatic disease at the time of diagnosis. The treatment of advanced GEP-NETs is nuanced, and only limited studies establish the optimal order of therapies. A multidisciplinary approach is required. Key factors in creating a treatment plan include: - Tumor grade - Tumor burden (how much disease is present) - Tumor location - Rate of progression - Symptoms - Comorbidities (other health conditions) Current systemic therapy options include somatostatin analogs (SSAs), capecitabine/temozolomide (oral chemotherapy), radioligand therapy with [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) for somatostatin receptor 2 (SSTR2)-positive tumors, everolimus, and tyrosine kinase inhibitors (TKIs). ## How PRRT Works PRRT with 177Lu-DOTATATE is a type of SSTR-targeting radionuclide therapy. It delivers cytotoxic (cell-killing) radiation directly to tumor cells. The treatment causes radiation-induced DNA damage and cell death through the beta radiation-emitting properties of **lutetium-177**. Because the radiation is attached to a molecule that binds to somatostatin receptors, the radiation concentrates in tumor tissue while largely sparing normal organs. The approval of PRRT in the United States in 2018 was largely driven by the publication of the **NETTER-1** trial. That study was a phase III trial comparing 177Lu-DOTATATE plus octreotide long-acting release (LAR) 30 mg once every 4 weeks to high-dose octreotide LAR (60 mg once every 4 weeks). The trial enrolled patients with advanced midgut SSTR-positive WD G1–G2 NETs (with Ki-67 ≤ 20%) whose disease had progressed on standard octreotide LAR. Patients received an activity of 200 mCi of 177Lu-DOTATATE every 8 weeks for a total of four cycles. ## How This Review Was Conducted The authors of this review included significant studies that have established treatment standards for patients with well-differentiated GEP-NETs treated with PRRT. Papers were selected based on their impact on the literature and their relevance to the discussion. The papers were identified through expert opinion and through a literature search. Clinical trials discussed in this review were selected based on the authors' assessment of their potential impact on the field. ## Key Findings: Evidence for PRRT ### The NETTER-1 Trial The NETTER-1 trial met its primary endpoint of prolonging **progression-free survival (PFS)** — the length of time during which the tumor does not grow. Median PFS was 8.4 months (95% CI: 5.8–9.1) with octreotide LAR alone. The endpoint was not reached in the PRRT arm. This difference was highly statistically significant (P < 0.001; hazard ratio (HR) = 0.21; 95% CI: 0.13–0.33). A hazard ratio of 0.21 means patients receiving PRRT had about a 79% lower risk of disease progression during the study period compared with the control group. Overall survival (OS) analysis at five years revealed a median OS of **48 months in the PRRT arm** compared to **36.3 months in the control group**. The difference in OS was not statistically significant, most likely due to a high crossover rate — meaning many patients in the control group later received PRRT, which can dilute the survival difference between groups. ### European Phase II Study Data Data from Europe in a single-arm phase II study of patients with GEP-NETs, bronchial NETs, and NETs of unknown primary treated with 177Lu-DOTATATE revealed: - Median PFS of 29 months - Median OS of 63 months - Longest median OS of 71 months in patients with pancreatic NETs Interestingly, the objective response rate (ORR — the percentage of patients whose tumors shrank measurably) in this study was **39%**, compared to **18%** in NETTER-1. Only 1–2% of patients achieved complete responses in both studies. Other prospective and retrospective studies have revealed similar response rates and survival outcomes. Although requiring further validation, newer blood-based tests known as the PRRT predictive quotient (PPQ) and NETest have been shown to predict responses to PRRT. ### The NETTER-2 Trial (More Recent Data) More recently, the phase III NETTER-2 trial compared 177Lu-DOTATATE plus octreotide 30 mg LAR every 4 weeks (treatment group) to high-dose octreotide 60 mg LAR every 4 weeks (control group). The study enrolled patients with advanced GEP-NETs that were: - Grade 2 with Ki-67 ≥ 10% and ≤ 20%, or - Grade 3 with Ki-67 > 20% and ≤ 55% All patients had SSTR-positive disease. The study revealed a median PFS of **8.5 months** (95% CI: 7.7–13.8) in the control group versus **22.8 months** (95% CI: 19.4–not estimated) in the 177Lu-DOTATATE group. This difference was highly significant (P < 0.0001; HR = 0.276; 95% CI: 0.182–0.418). The objective response rate (ORR) was **43%** in the study arm, with consistent benefit across all subgroups, including both grades and primary tumor sites. ## Quality of Life and Symptom Control In addition to radiographic (imaging) control, PRRT is also effective in controlling tumor-related symptoms. In the health-related quality-of-life (QoL) analysis of NETTER-1, patients treated with 177Lu-DOTATATE had a significant improvement in time to QoL deterioration for several measures compared to patients treated with high-dose octreotide LAR. These measures included: - Global health - Physical functioning - Diarrhea - Pain - Body image - Disease-related worries - Fatigue Similarly, Khan and colleagues reported an improvement in health-related QoL, as well as in performance status and symptoms, in patients with GEP and bronchial NETs treated with PRRT. Other studies have also reported an improvement in symptoms in patients with functional pancreatic NETs (tumors that secrete hormones and cause hormone-related syndromes) and refractory carcinoid symptoms in patients with small bowel NETs. One important caution: there is a possibility of developing a **flare** in functional symptoms, and rarely a hormonal crisis, during or shortly after administration of PRRT. ## Imaging Before and During PRRT In order to be eligible for 177Lu-DOTATATE PRRT, SSTR imaging must be performed beforehand. SSTR scintigraphy (an older imaging method) was used for inclusion criteria in NETTER-1. It has now been replaced by **SSTR-PET** using DOTA-conjugated peptide (68Ga-DOTATATE, 68Ga-DOTATOC, or 64Cu-DOTATATE). SSTR-PET is now standard because of its substantially superior lesion detection rate. Positive uptake on SSTR-PET is defined as having a higher intensity of uptake or radiopharmaceutical concentration compared to normal organs. This is typically quantified using a PET measurement known as **standardized uptake value (SUV)**. There are no specific SUV cutoffs to determine PRRT eligibility. Instead, a multidisciplinary discussion with the nuclear medicine team is necessary to determine whether there is sufficient positive uptake for the patient to derive meaningful benefit from PRRT. This discussion must also consider other potential treatment options. There are retrospective studies suggesting that pretreatment SSTR-PET uptake can serve as both: - A predictive marker for response to PRRT - A prognostic marker (a predictor of overall outcome) for NET patients These findings have not yet been validated prospectively. As mentioned earlier, high-grade NENs can either lose SSTR expression or have heterogeneous SSTR expression on imaging. Very rarely, well-differentiated low-grade NETs can also have absence of SSTR expression, resulting in negative SSTR imaging. The increased proliferation rate and aggressive biology of high-grade NENs present an opportunity to use **18F-FDG PET/CT** for accurate staging when uptake on SSTR imaging is either negative or heterogeneous. FDG PET measures glucose metabolism, which is typically higher in more aggressive tumors. High uptake on 18F-FDG PET/CT is associated with: - Lower objective response rate (ORR) after PRRT - Shorter progression-free survival (PFS) - Shorter overall survival (OS) - Poor prognosis overall While there is a lack of consensus on whether 18F-FDG PET should be obtained at baseline for patients with high-grade NENs, many NET oncologists obtain both SSTR and FDG PET scans at diagnosis. Chan and colleagues proposed the **NETPET grading system**, which incorporates the degree of uptake on both SSTR and FDG PET/CT performed within a month of each other. In their study, the highest of five grades — representing FDG uptake greater than SSTR uptake — demonstrated the lowest overall survival. This finding supports its use as a potential prognostic imaging biomarker. Typically, diagnostic imaging for response assessment is performed **1–3 months after completion of four doses of PRRT**. Although not currently standard, there may be a role for individualized dosimetric assessments using post-177Lu-DOTATATE scintigraphy with SPECT/CT for treatment planning. This approach is being studied in several ongoing clinical trials. Outside of dosimetric assessments, imaging between cycles is done every 3–4 months at some centers, particularly if there is concern for clinical progression. Patients should know that a flare in functional symptoms, and rarely a hormonal crisis, can occur during or shortly after PRRT administration. A transient rise in tumor markers and liver function enzymes is also sometimes seen. This needs to be considered when deciding whether to obtain mid-treatment imaging. There are currently no specific guidelines on whether to use anatomical imaging or SSTR functional imaging for response assessment. In most cases, cross-sectional imaging with contrast-enhanced CT, or MRI for liver-predominant disease, is sufficient. It is important to understand the possibility of **pseudo-progression** — an apparent worsening on anatomical imaging during or shortly after completion of PRRT. This occurs due to a transient increase in tumor size, most likely from radiation-induced inflammation and edema. Functional imaging can help distinguish pseudo-progression from true progression. The subsequent timing and choice of imaging depend on tumor biology, burden of disease, and response to PRRT. ## Sequencing PRRT in Advanced GEP-NETs Of the treatment options for advanced GEP-NETs, the timing and sequencing of PRRT should be evaluated based on several factors: - Tumor biology - Disease burden - Primary tumor site as well as metastatic sites - The need for tumor response - Comorbidities Until the NETTER-2 trial, most studies on patients treated with 177Lu-DOTATATE involved patients whose disease had progressed after first-line SSA therapy. NETTER-2 established a role for PRRT in the **frontline setting** for patients with advanced grade 2 or 3 disease. For most patients with advanced low-grade GEP-NETs, first-line treatment with SSA alone is effective in providing long-term symptom and disease control. Surgical debulking and liver-directed therapy should also be considered and discussed in a multidisciplinary setting. ### Second-Line Treatment of Low-Grade GEP-NETs For second-line treatment of low-grade GEP-NETs, there is not one optimal sequence. Each patient's treatment should be individualized and discussed in a multidisciplinary setting. Treatment options include: - Everolimus - Capecitabine/temozolomide - Tyrosine kinase inhibitors (TKIs): sunitinib for pancreatic NETs and cabozantinib for midgut and pancreatic NETs - 177Lu-DOTATATE For patients with high-volume or symptomatic low-grade GEP-NETs, incorporating 177Lu-DOTATATE over everolimus and TKIs is reasonable. For patients where accelerated cytoreduction (rapid tumor shrinkage) is required, sequencing capecitabine/temozolomide over other treatment options should be considered. For patients with low-grade midgut NETs, responses with capecitabine/temozolomide are not as impressive. Sequencing 177Lu-DOTATATE earlier in treatment for symptomatic patients is reasonable. ### PRRT After Other Therapies and in the Frontline Setting Data suggest that sequencing 177Lu-based PRRT after everolimus and after cytotoxic chemotherapy is safe and feasible in patients with GEP-NETs. The NETTER-2 phase III trial showed an improvement in median PFS of about 14 months with first-line 177Lu-DOTATATE plus octreotide 30 mg LAR every 4 weeks, compared to high-dose octreotide 60 mg LAR every 4 weeks. This benefit was seen in patients with grade 2 (Ki-67 ≥ 10% and ≤ 20%) and grade 3 (Ki-67 > 20% and ≤ 55%) SSTR-positive advanced GEP-NETs. High-grade NETs include a wide range of Ki-67 values and can have significantly varied biology, ranging from relatively indolent (slow-growing) disease to rapidly progressive tumors. The impressive improvement in median PFS from NETTER-2 should be carefully assessed together with each individual patient's characteristics. First-line PRRT should be considered in this patient population. However, it may not be indicated in: - Asymptomatic patients - Patients with low symptom burden - Patients with low disease burden - Patients with slower growth rates For patients with rapidly progressive, high-volume disease, or patients in **visceral crisis** (a life-threatening situation caused by rapid tumor growth or hormone secretion), cytotoxic chemotherapy should be considered over PRRT. ## Unique Challenges and Safety Considerations When considering PRRT, it is critical to carefully individualize the treatment plan to each NET patient's unique needs. This includes consideration of tumor biology, grade, prior treatments, and the known tempo of the patient's disease course. PRRT was approved based on the NETTER-1 study. That study selected healthier patients with robust organ function. The exclusion criteria for NETTER-1 included patients with creatinine clearance of less than 50 mL/min, as well as low albumin levels. The study selected patients who would be less likely to experience known toxicities of radioligand therapy, with particular emphasis on patients with normal kidney function and normal liver function. In the real world, however, exceptions have to be made. Patients who fall outside the specific parameters in NETTER-1 can still benefit from PRRT. Understanding the impact of PRRT in unique situations — including decreased organ function, high disease burden, prior cytotoxic treatments, and prior radiation — can help oncologists tailor treatment to each individual NET patient. ### PRRT in Patients with Chronic Kidney Disease (CKD) Concern for renal (kidney) toxicity from PRRT is based on the risk of radiation damage to the kidneys. With renal protective amino acid infusions, the risk of acute kidney toxicity in patients with creatinine clearance greater than 50 mL/min is low. An important question remains for patients with creatinine clearance below 50 mL/min. There is concern that, with decreasing renal function, increased radioligand peptide is absorbed in the proximal tubule of the kidney, raising the risk of radiation-induced nephrotoxicity (kidney damage). However, a subgroup analysis of NETTER-1 provided reassuring data. In the 177Lu-DOTATATE arm, there were: - 11 patients with mild baseline renal dysfunction (creatinine clearance 50–60 mL/min) - 13 patients with moderate dysfunction (creatinine clearance below 50 mL/min) Those patients with mild or moderate renal dysfunction had no increased risk of renal toxicity or decompensation of renal function over time. Another prospective study of 177Lu-DOTATATE in 51 patients found that the median creatinine for the entire group increased from baseline one year after treatment. Seventeen patients had a more severe reduction in creatinine clearance of 20% or greater. Patients with other risk factors for chronic kidney disease, including hypertension and diabetes, were at highest risk of renal decompensation with PRRT treatment. The authors described one patient in the group with a more severe decline in renal function after PRRT that was associated with hydronephrosis (kidney swelling caused by urine backup). Key safety points for special situations based on the review: - **Chronic kidney disease:** PRRT appears safe in most patients with creatinine clearance above 30 mL/min. Consider dose reduction and additional hydration. Hydronephrosis must be corrected before PRRT. - **Cytopenia (low blood counts) or pre-existing CHIP (clonal hematopoiesis of indeterminate potential):** Hematologic toxicity is a potential risk with PRRT. Consider dose reduction and alternatives in high-risk patients. This is an ongoing area of active research. - **Peritoneal metastatic disease (disease spread in the abdominal lining):** PRRT is well tolerated even with peritoneal disease. For those at highest risk, consider prophylactic steroids after treatment. - **High-volume liver metastasis:** PRRT is well tolerated in many patients with a high burden of metastatic liver disease. Liver function is a more important parameter of the risk of hepatic toxicity than tumor volume or burden in the liver. - **Sequencing with prior Y90 radioembolization:** Patients with a high volume of prior Y90 radioembolization treatment may be at a higher risk of hepatotoxicity (liver damage) after PRRT. - **Re-treatment with PRRT:** Salvage PRRT with two additional cycles can be done safely and effectively in patients who have already received an initial four cycles of PRRT. ### Hydronephrosis and Kidney Risk Patients with NENs, particularly midgut NENs, are at an increased risk of hydronephrosis. This can be related to metastatic tumor deposits or to mesenteric fibrosis (scarring in the tissue that supports the intestines). The risk of renal toxicity in patients with hydronephrosis is high. This is because radioligand particles can pool in the kidney, increasing radiation exposure. Patients with hydronephrosis require close collaboration with urology and correction of the hydronephrosis before PRRT, in order to prevent radiation exposure and permanent renal toxicity. Retrospective studies have also evaluated the risk of renal decompensation in patients receiving PRRT. One single-center retrospective analysis identified 33 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m². Of these, 26 had more severe kidney disease with a GFR of 45–60 mL/min/1.73 m², and 7 had GFR levels below that range. ## Ongoing Clinical Trials Several ongoing clinical trials are exploring ways to improve PRRT and better define its place in treatment. These are relevant to patients discussing PRRT with their care team. - **Dosimetry-based PRRT:** Trials such as DOBATOC (NCT04917484) and LUMOD-ID (NCT06395402) compare standard PRRT dosing to individualized doses based on patient-specific dosimetry measurements. - **PRRT combined with chemotherapy:** An Alliance-led randomized phase II trial (NCT05247905) is comparing capecitabine and temozolomide combined with 177Lu-DOTATATE for advanced pancreatic NETs. - **Newer radiopharmaceuticals:** The COMPOSE trial (NCT04919226) is testing 177Lu-EDOTREOTIDE versus best standard of care in grade 2/3 GEP-NETs. The COMPETE trial (NCT03049189) is comparing 177Lu-EDOTREOTIDE PRRT to everolimus in well-differentiated GEP-NETs. - **Neoadjuvant PRRT:** A phase I trial (NCT04609592) is studying PRRT before cytoreductive surgery in patients with grade 1 or 2 SSTR-positive GEP-NETs. - **PRRT combined with PARP inhibitors:** The PRRT-PARPis trial (NCT05870423) tests olaparib with PRRT after progression on initial PRRT. Another trial (NCT05053854) tests talazoparib in combination with 177Lu-DOTA-Octreotate PRRT. - **PRRT combined with other drugs:** A phase II trial (NCT05724108) is testing the drug triapine with 177Lu-DOTATATE. An Imperial College London trial (NCT05178693) studies ASTX727 in combination with Lutathera. - **New delivery forms:** A phase I trial (NCT05475210) studies 177Lu-DOTA-EB-TATE in advanced GEP-NETs, as does the ALPHAMEDIX02 trial (NCT05153772) with a targeted alpha-emitter therapy (212Pb-DOTAMTATE) in PRRT-naïve and previously treated NET patients. - **Retreatment and next steps:** The NETRETREAT trial (NCT05773274) compares retreatment with 177Lu-DOTATATE to everolimus in metastatic unresectable midgut NETs. The ACTION-1 trial (NCT05477576) studies RYZ101 compared with standard of care in patients who progressed after 177Lu-SSA therapy. - **NETTER-3** (NCT06784752) is a phase III randomized trial evaluating PRRT versus standard of care in patients with grade 1 and grade 2 advanced GEP-NETs. ## Clinical Implications PRRT has proven effective for patients with advanced, somatostatin receptor-positive NETs. This is especially true for patients with inoperable tumors or those whose disease is progressing after other therapies. PRRT plays a vital role in the overall management of GEP-NETs. However, its sequencing with other treatments remains complex. Current evidence supports using PRRT both early and late in the treatment journey, depending on individual patient factors. The NETTER-2 results are practice-changing for grade 2 and grade 3 disease. Select patients with higher Ki-67 levels now have an option for PRRT as their first treatment. At the same time, not every patient needs early PRRT. Patients with slow-growing, low-burden, low-symptom disease may do well with an SSA first. For patients with high-volume or symptomatic low-grade tumors, PRRT appears to be a reasonable choice over everolimus and TKIs. If rapid tumor shrinkage is needed, chemotherapy may be preferred. In small bowel NETs, where chemotherapy responses are less impressive, earlier PRRT for symptom control is a sensible option. The safety data support careful evaluation of kidney function, prior liver-directed therapy, and blood counts before starting PRRT. Most patients with mild to moderate kidney impairment can be treated safely with appropriate precautions. ## Limitations This article is a review, not a single clinical trial. The authors selected studies based on expert opinion and perceived impact, which carries some risk of selection bias. Several important questions remain unanswered. The overall survival benefit in NETTER-1 did not reach statistical significance, likely because many patients in the control group crossed over to receive PRRT. This crossover makes it harder to prove a survival advantage from PRRT alone. The role of SSTR-PET uptake as a predictive or prognostic marker has not been validated prospectively. There are no standard SUV cutoffs to determine eligibility. The optimal sequencing of PRRT with other treatments is not established by large, randomized, head-to-head trials. Much of the guidance in second-line treatment of low-grade tumors is based on smaller studies and expert consensus rather than definitive phase III data. Additionally, biomarkers such as the PPQ and NETest show promise for predicting response to PRRT, but they still require further validation before becoming routine clinical tools. ## Recommendations for Patients Patients with advanced GEP-NETs should be treated at centers with a multidisciplinary NET team. This team typically includes medical oncologists, nuclear medicine specialists, surgeons, radiologists, and pathologists. Ask your care team the following questions when discussing PRRT: 1. Did my tumor test positive on SSTR-PET imaging, and is the uptake high enough to expect a meaningful benefit? 1. What is my tumor grade and Ki-67 index? Does this suggest I might benefit from PRRT early in my treatment? 1. What is my current kidney function, and do I need any additional evaluation such as a renal scan or correction of hydronephrosis before starting PRRT? 1. What other treatments might be appropriate before or after PRRT, based on my specific tumor type and symptoms? 1. If my tumor is growing rapidly or causing severe symptoms, is chemotherapy a better first option than PRRT? 1. Is there a clinical trial available that might improve my treatment outcomes? If PRRT is recommended, patients typically receive four cycles given approximately 8 weeks apart. Each treatment is followed by radiation safety precautions for a period of time, which your team will explain. Monitoring after PRRT generally includes imaging at 1–3 months after treatment completion, with follow-up scans every 3–6 months depending on tumor biology and clinical status. Remember that apparent tumor growth on early scans after PRRT may be pseudo-progression from inflammation rather than true resistance. Ask your doctor whether functional imaging could help clarify the picture. Patients with kidney disease, prior liver radiation, blood count abnormalities, or prior chemotherapy should discuss whether dose adjustments or additional protective measures are warranted. Surgery to correct hydronephrosis should be completed before PRRT when needed. Finally, because the field is evolving rapidly, patients are encouraged to seek updated information and consider clinical trials exploring better PRRT delivery, combination therapies, and newer agents. ## Frequently Asked Questions ### What is PRRT and how does it work? PRRT (peptide receptor radionuclide therapy) is a targeted radiation treatment. It uses a molecule that binds to somatostatin receptors on tumor cells, carrying the radioactive isotope lutetium-177. This delivers cell-killing beta radiation directly to the tumor, causing DNA damage and cell death, while largely sparing normal organs. It is used for advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors that express somatostatin receptors. ### Am I eligible for PRRT? Eligibility requires a positive somatostatin receptor PET scan showing sufficient uptake. There are no specific SUV cutoffs; a multidisciplinary team decides if uptake is high enough for meaningful benefit. PRRT is approved for SSTR-positive advanced GEP-NETs. Patients with poor kidney function (creatinine clearance below 50 mL/min) were excluded from the NETTER-1 trial, but real-world exceptions are made. Your tumor grade, prior treatments, and overall health are also considered. ### What does the progression-free survival number mean? Progression-free survival (PFS) is the time during which the tumor does not grow. In the NETTER-1 trial, median PFS was 8.4 months with octreotide alone, while it was not reached in the PRRT arm. In NETTER-2, median PFS was 8.5 months in the control group versus 22.8 months with PRRT. These numbers describe group averages, not individual outcomes. ### What are the main risks or side effects of PRRT? PRRT can cause kidney damage, especially if kidney function is already reduced or if hydronephrosis is present. Blood count suppression (cytopenia) is possible. A flare in functional symptoms, and rarely a hormonal crisis, can occur during or shortly after treatment. Pseudo-progression—apparent tumor growth on scans due to inflammation—may happen. Prior Y90 radioembolization may increase liver toxicity risk. Your team will monitor and take precautions. ### How is PRRT given and what happens after? PRRT is usually given as four cycles, approximately 8 weeks apart. Each treatment is followed by radiation safety precautions for a period of time, which your team will explain. After completing treatment, imaging is typically done 1–3 months later, with follow-up scans every 3–6 months depending on tumor biology and clinical status. A transient rise in tumor markers and liver enzymes can sometimes be seen. ### Can PRRT be used as a first treatment? Yes, for some patients. The NETTER-2 trial showed that first-line PRRT plus octreotide improved median progression-free survival by about 14 months compared to high-dose octreotide in patients with grade 2 (Ki-67 10–20%) or grade 3 (Ki-67 >20–55%) SSTR-positive advanced GEP-NETs. However, first-line PRRT may not be indicated for asymptomatic patients, those with low symptom burden, low disease burden, or slower growth rates. ### What should I ask my care team about PRRT? Ask: Did my tumor test positive on SSTR-PET, and is uptake high enough? What is my tumor grade and Ki-67? What is my kidney function, and do I need a renal scan or hydronephrosis correction? What other treatments might be appropriate before or after PRRT? If my tumor is growing rapidly or causing severe symptoms, is chemotherapy a better first option? Is there a clinical trial available? ### When should a patient with advanced GEP-NETs considering PRRT seek a second opinion? Seek a second opinion when the timing or sequence of PRRT is unclear. Sequencing PRRT with somatostatin analogs, everolimus, tyrosine kinase inhibitors, or chemotherapy is complex, and no large randomized trials establish one optimal order. A second review can help confirm tumor grade and Ki-67, assess SSTR-PET uptake, and evaluate kidney function, prior liver-directed therapy, and blood counts before treatment. Patients with high-volume or symptomatic low-grade tumors, or grade 2 and 3 disease, may benefit from multidisciplinary input on whether PRRT should come earlier or later. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original article title:** PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). **Authors:** Corbett V, Gupta G, Chauhan A. **Journal:** Endocrine-Related Cancer (2026) 33 e250495. Published by Bioscientifica Ltd. Article received 26 November 2025, accepted 26 February 2026, available online 2 March 2026, version of record published 23 March 2026. Correspondence: Aman Chauhan, MD, Department of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, UCSF: aman.chauhan@ucsf.edu This patient-friendly article is based on peer-reviewed research. **Note:** This article is licensed under a Creative Commons Attribution 4.0 International License. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/prrt-for-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-a-patients-guide-to-treatment-and-sequencing